Browse the corpus

REFERENCES Adams CD, Szumita PM, Baroletti SA, et al, “Azacitidine-Induced Interstitial and Alveolar Fibrosis in a Patient With Myelodysplastic Syndrome,” Pharmacother , 2006, 25(5):765-8. Hurwitz CA, Mounce KG, and Grier HE, “Treatment of Patients With Acute Myelogenous Leukemia: Review of Clinical Trials of the Past Decade,” J Pediatr Hematol Oncol , 1995, 17(3):185-97. [PubMed 7620918 ] Jehn U, “Long-Term Outcome of Postremission Chemotherapy for Adults With Acute Myeloid Leukemia Using Different Dose-Intensities,” Leuk Lymphoma , 1994, 15(1-2):99-112. [PubMed 7532060 ] Kornblith AB, Herndon JE 2nd, Silverman LR, et al, “Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study,” J Clin Oncol , 2002, 20(10):2441-52. [PubMed 12011121 ] Kritz AD, Raptis G, Menendez-Botet C, et al, “Pilot Study of 5-Azacytidine (5-AZA) and Carboplatin (CBDCA) in Patients With Relapsed/Refractory Leukemia,” Am J Hematol , 1996, 51(2):117-21. [PubMed 8579051 ] Lyons RM, Cosgriff TM, Modi SS, et al, “Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndrome,” J Clin Oncol , 2009, 27(11):1850-6. [PubMed 19255328 ] National Comprehensive Cancer Network® (NCCN), “Practice Guidelines in Oncology™: Acute Myeloid Leukemia,” Version 1, 2009. Available at file://www.nccn.org/professionals/physician_gls/PDF/aml.pdf National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Myelodysplastic Syndromes,” Version 2.2009. Available at file://www.nccn.org/professionals/physician_gls/PDF/mds.pdf National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Peterson BA, Collins AJ, Vogelzang NJ, et al, “5-Azacytidine and Renal Tubular Dysfunction,” Blood, 1981, 57(1):182-5. [PubMed 6160887 ] Rees JK, Gray RG, and Wheatley K, “Dose Intensification in Acute Myeloid Leukaemia: Greater Effectiveness at Lower Cost. Principal Report of the Medical Research Council's AML9 Study. MRC Leukaemia in Adults Working Party,” Br J Haematol , 1996, 94(1):89-98. [PubMed 8757514 ]

Peterson BA, Collins AJ, Vogelzang NJ, et al, “5-Azacytidine and Renal Tubular Dysfunction,” Blood, 1981, 57(1):182-5. [PubMed 6160887 ] Rees JK, Gray RG, and Wheatley K, “Dose Intensification in Acute Myeloid Leukaemia: Greater Effectiveness at Lower Cost. Principal Report of the Medical Research Council's AML9 Study. MRC Leukaemia in Adults Working Party,” Br J Haematol , 1996, 94(1):89-98. [PubMed 8757514 ] Silverman LR, Demakos EP, Peterson BL, et al, “Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B,” J Clin Oncol , 2002, 20(10):2429-40. [PubMed 12011120 ] Silverman LR, Holland JF, Weinberg RS, et al, “Effects of Treatment With 5-Azacytidine on the in vivo and in vitro Hematopoiesis in Patients With Myelodysplastic Syndromes,” Leukemia , 1993, 7(Suppl 1):21-9. [PubMed 7683352 ] Silverman LR, McKenzie DR, Peterson BL, et al,”Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B,” J Clin Oncol , 2006, 24(24):3895-903. [PubMed 16921040 ] Steuber CP, Krischer J, Holbrook T, et al, “Therapy of Refractory or Recurrent Childhood Acute Myeloid Leukemia Using Amsacrine and Etoposide With or Without Azacitidine: A Pediatric Oncology Group Randomized Phase II Study,” J Clin Oncol , 1996, 14(5):1521-5. [PubMed 8622066 ] Steuber CP, Holbrook T, Camitta B, et al, “Toxicity Trials of Amsacrine (AMSA) and Etoposide ± Azacitidine (AZ) in Childhood Acute Nonlymphocytic Leukemia (ANLL): A Pilot Study,” Invest New Drugs , 1991, 9(2):181-4. [PubMed 1714886 ] Sudan N, Rossetti JM, Shadduck RK, et al, “Treatment of Acute Myelogenous Leukemia With Outpatient Azacitidine,” Cancer , 2006, 107(8):1839-43. [PubMed 16967444 ] Volger WR, Weiner RS, Moore JO, et al, “Long-Term Follow-up of a Randomized Postinduction Therapy Trial in Acute Myelogenous Leukemia (A Southeastern Cancer Study Group Trial),” Leukemia , 1995, 9(9):1456-60. [PubMed 7544851 ] Topic 8797 Version 39.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]